MarketLens
Sign Up

Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market

3 months ago
SHARE THIS ON:

Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum

Insulet is targeting elevated early attrition among certain Type 2 diabetes customers while expanding automated insulin delivery adoption across underpenetrated markets, per COO Eric Benjamin. The com...
Stock News•2 months ago

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Abbott is expanding across diabetes care, oncology diagnostics and heart devices via new launches and acquisitions, creating multiple growth paths.
Stock News•3 months ago

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech's CGM+ platform validated in over 5,000 hours of clinical data to distinguish false nocturnal compression lows from true hypoglycemia, addressing a key CGM limitation within the $15B g...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help